Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
UST sale of HealthProof to Bain
We advised UST on the transaction
Precigen $125 million financing
We advised Precigen on the loan agreement
Ascletis HK$861.98 million placement of shares and top-up subscription
We advised the placing agent on the placement and the top-up subscription
Cardinal Health $1 billion notes offering
The investment-grade notes are due 2030 and 2035
Eli Lilly $6.75 billion notes offering
The investment-grade offering consisted of seven tranches
Zoetis $1.85 billion senior notes offering
The investment-grade notes are due 2028 and 2035
Tempus AI $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Amneal Pharmaceuticals $600 million notes offering
We advised Amneal Pharmaceuticals on its high-yield notes offering
GSK agreements with Hengrui Pharma to develop up to 12 innovative medicines
We are advising GSK on the transaction
Tempus AI $750 million convertible senior notes offering
The 0.75% convertible senior notes are due 2030